BioPharmSignal logoBioPharmSignal

Biotech News

Fulgent Reports First Quarter 2026 Financial Results

Fulgent Genetics, Inc. (FLGT)Fulgent Genetics, Inc.2026-06-25 13:46 ESTEarnings

Reiterates revenue guidance for fiscal year 2026 Executed on stock repurchase program; purchased approximately 2.6 million shares in the first quarter of 2026 using $40.1 million in cash Revenue of $71.1 million GAAP gross profit of $21.5 million, or GAAP gross margin of 30.2%; Non-GAAP gross

Open original release

Related news

FLGTFulgent Genetics, Inc.2026-06-25 13:46 EST

Fulgent Presents Updated FID-007 Data at ASCO 2026

FLGTFulgent Genetics, Inc.2026-06-25 13:46 EST

Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting

FLGTFulgent Genetics, Inc.2026-06-25 13:46 EST

Fulgent Shares Preliminary Data from Poster Presentation at ESMO 2025 Conference

FLGTFulgent Genetics, Inc.2026-06-25 13:46 EST

Fulgent Reports Third Quarter 2025 Financial Results

FLGTFulgent Genetics, Inc.2026-06-25 13:46 EST

Fulgent to Participate in Upcoming Conferences

FLGTFulgent Genetics, Inc.2026-06-25 13:46 EST

Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx

FLGTFulgent Genetics, Inc.2026-06-25 13:46 EST

Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026

FLGTFulgent Genetics, Inc.2026-06-25 13:46 EST

Fulgent Reports Fourth Quarter and Full Year 2025 Financial Results

FLGTFulgent Genetics, Inc.2026-06-25 13:46 EST

Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx

FLGTFulgent Genetics, Inc.2026-06-25 13:46 EST

Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026

View all latest news

Fulgent Genetics, Inc.

Fulgent Genetics is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

FLGTFulgent Genetics, Inc.2026-06-26 11:23 EST

Fulgent Presents Updated FID-007 Data at ASCO 2026

FLGTFulgent Genetics, Inc.2026-06-26 11:23 EST

Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting

FLGTFulgent Genetics, Inc.2026-06-26 11:23 EST

Fulgent Shares Preliminary Data from Poster Presentation at ESMO 2025 Conference

FLGTFulgent Genetics, Inc.2026-06-26 11:23 EST

Fulgent Reports Third Quarter 2025 Financial Results

FLGTFulgent Genetics, Inc.2026-06-26 11:23 EST

Fulgent to Participate in Upcoming Conferences

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biotechnology
Location
United States